By Bhanvi Satija and Pushkala Aripaka LONDON, Feb 4 (Reuters) - GSK's new CEO Luke Miels said on Wednesday that the drugmaker ...
Replacing animal testing with alternate methodologies in preclinical drug trials holds potential for the development of ...
Morning Overview on MSN
Nvidia doubles down on AI drug discovery in shocking new push
Nvidia is no longer content to be the chip supplier behind other companies’ biotech ambitions. With a multibillion dollar ...
A major step toward simpler drug development has been taken at the University of Gothenburg. In a new study, researchers have developed stable boron-fluorine compounds that make it possible to ...
Add Yahoo as a preferred source to see more of our stories on Google. A new analysis of 341 pivotal drug trials shows that only a tiny fraction reflect the racial and ethnic mix of the United States.
Korean Biosimilar Firms Capitalize on Global Patent Expirations Samsung Bioepis, Celltrion Target Keytruda, Dupixent ...
In the UK, there was a case where TGN1412, an immunotherapy under development, triggered a cytokine storm within hours of administration to humans, leading to multiple organ failure. Another example, ...
New approach methodologies (NAMs) aim to address the limitations of animal models by assessing drug efficacy and safety in a more ethical, human-relevant way. The term ‘NAMs’ encompasses several ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results